×
Sign up for email alerts · NYSE: ADC$56.56 · CHANGE$0.73(1.31%) · MARKET CAP$5.7B · VOLUME1.2M.
People also ask
Latest news for ADC Therapeutics, a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation ADCs.
Find answers to frequently asked questions from investors about ADC Therapeutics, a leading clinical-stage oncology biotechnology company, developing.
This investor relations area will give you insight to our annual reports and financial statements for ADC Krone India Communications Ltd (Earlier KRONE ...